Next generation Malaria drug shows promise
September 6, 2010Research and Development malaria
A Novartis-led collaboration has discovered a novel anti-malarial candidate that could become the first new treatment for the disease in …
Olivier Bohuon takes post at Pierre Fabre
September 6, 2010Sales and Marketing Pierre Fabre, appointment, sales and marketing
French pharma company Pierre Fabre has officially appointed Olivier Bohuon to take over from Jean-Pierre Garnier as chief executive. Olivier’s …
Sanofi’s Multaq in pole position for AF market
September 6, 2010Sales and Marketing Multaq, Sanofi-Aventis, atrial fibrilation
New European Society of Cardiology guidelines on treating atrial fibrillation (AF) include a recommendation for Sanofi-Aventis’ Multaq. The endorsement is …
Pradaxa, Xarelto and apixaban vie for attention
September 6, 2010Research and Development, Sales and Marketing Pradaxa, Xarelto, apixaban, atrial fibrilation
New data has intensified the competition between three rival would-be cardiology blockbusters. Boehringer Ingelheim’s Pradaxa (dabigatran) and Bayer’s Xarelto (rivaroxaban) …
Watchdog resignation forced ‘to appease pharma’
September 6, 2010Sales and Marketing Germany, IQWIG
The head of Germany’s medicines cost-effectiveness watchdog was forced to resign because he was a vocal critic of the pharma …
Huntsworth makes European strategy appointment
September 3, 2010Medical Communications Huntsworth, appointment, medical communications
UK communications company Huntsworth Health has appointed Annabelle Sandeman as European Director Strategic Development. She will report to chief executive …
Roche: ‘We will work to eliminate barriers to social media’
September 3, 2010Medical Communications Digital Pharma blog, Roche, social media
Last month Roche broke new ground for pharma by publishing its Social Media Principles (full details of which you can …
Roche set for jobs cuts from 2011
September 3, 2010Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, job cuts
Roche has confirmed it will take wide-ranging steps to reduce costs, following local reports the Swiss pharma firm was poised …
AZ’s Seroquel extends European licence
September 3, 2010Sales and Marketing AstraZeneca, Seroquel
AstraZeneca’s controversial anti-psychotic drug Seroquel has been given the green light in Europe as an add-on treatment for serious depressive …
Merck wins double approval in Europe
September 3, 2010Sales and Marketing Brinavess, Merck & Co, Syncrest, merck sharp and dohme
European regulators have given the green light for two of Merck & Co’s new drugs, licensing its anti-psychotic treatment Sycrest …
Industry supports Australia’s new price deal
September 3, 2010Sales and Marketing Australia, global pricing, price cuts
Australia’s pharmaceutical industry is urging the country’s legislators to pass a new medicines pricing bill that aims to save Aus$1.9 …
UK biotech body elects new chairman
September 3, 2010Research and Development BIA, appointment, research and development
Cellzome’s president and chief executive Tim Edwards has been elected chairman of the BioIndustry Association. Commenting on his election he …
Contract research news in brief
September 3, 2010Research and Development Cyprotex, Epistem, INC Research, Jubilant, Laxal Pharma
A round-up of recent news from the CRO sector, featuring updates from Cyprotex, INC Research, Laxai Pharma, Asuragen, Jubilant Organosys …
Nigel Brooksby joins Prism Ideas
September 2, 2010Medical Communications, Research and Development Prism Ideas, appointment, medical communications, research and development
Former Sanofi-Aventis UK chairman and managing director Nigel Brooksby has joined Cheshire, UK-based Prism Ideas as non-executive chairman. The medical …
Abbott’s Meridia ‘increases heart attack risk’
September 2, 2010Sales and Marketing Abbott, Meridia, drug safety
Abbott’s weight-loss drug Meridia increases the risk of stroke and heart attack in patients with heart disease, according a study …
Genzyme available for ‘fair value’, says Termeer
September 2, 2010Research and Development, Sales and Marketing Genzyme, Sanofi-Aventis
Genzyme’s chief executive Henri Termeer has said his company could be for sale to Sanofi-Aventis if it offers a ‘fair …
Pfizer acquires ‘protein misfolding’ specialist
September 2, 2010Research and Development FoldRx, Pfizer, cystic fibrosis
Pfizer has bolstered its presence in rare and orphan diseases with the acquisition of FoldRx, a US drug discovery firm …
Cephalon chairman takes leave of absence
September 2, 2010Research and Development, Sales and Marketing Cephalon, appointment, research and development, sales and marketing
Cephalon’s chairman and chief executive Frank Baldino Jr is taking a medical leave of absence with immediate effect. The company …
CME Spotlight: Reshaping the healthcare conversation
September 2, 2010Medical Communications CME Spotlight
In a recent conversation with the head of an international group of medical agencies, I was somewhat surprised to hear …
Digital Pharma: Augmented reality gateway for Bayer haemophilia site
September 1, 2010Medical Communications Digital Pharma blog, augmented reality, disease awareness campaigns, haemophilia
Bayer Healthcare has launched a new disease awareness campaign that uses augmented reality techniques to engage with its target audience. …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
